Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The ESA Disconnect Between FDA and CMS

This article was originally published in RPM Report

Executive Summary

Another major decision is looming at CMS on whether to open up a national coverage analysis for ESAs in the renal disease area-a MEDCAC meeting appears to be the first step. The Medicare agency previously jumped out in front of FDA on a coverage decision in the oncology setting. This time, it appears that CMS will wait to hear what FDA has to say. But FDA isn't paying much attention to CMS.

You may also be interested in...

CMS “Anemia Management” Quality Measure Relies on Monthly ESA/Hemoglobin Reports and Transfusion Level Monitoring

CMS taking a watch-and-monitor approach to controlling the use of ESAs in dialysis for 2013. That approach steps back from the trend of the past few years to specify more restrictive treatment levels to drive down further use of the products and represents a long, hard-fought success by Amgen and J&J to redefine the safety debate from when to use ESAs to efforts to avoid transfusions.

The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS

The long-awaited Risk Evaluation & Mitigation Strategy for Aranesp and Procrit is here. For the oncology indication, it requires provider training program enrollment. It may not seem like the best outcome for Amgen and J&J, but there are some upsides.

Amgen's D-mab: The New EPO

D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts